Monday, December 23, 2024
HomeTagsOral 3CLpro

Oral 3CLpro

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Ascletis Pharma Inc. announces that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics